ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Mainz BioMed NV

Mainz BioMed NV (MYNZ)

0.2485
-0.0015
(-0.60%)
Cerrado 14 Noviembre 3:00PM
0.25
0.0015
(0.60%)
Fuera de horario: 6:57PM

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
0.25
Postura de Compra
0.248
Postura de Venta
0.25
Volume Operado de la Acción
4,797,140
0.224 Rango del Día 0.26
0.1852 Rango de 52 semanas 1.79
Capitalización de Mercado [m]
Precio Anterior
0.25
Precio de Apertura
0.257
Última hora de negociación
Volumen financiero
US$ 1,169,113
Precio Promedio Ponderado
0.243711
Volumen promedio (3 m)
3,205,822
Acciones en circulación
21,165,482
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
0.00
Beneficio por acción (BPA)
-
turnover
895k
Beneficio neto
-26.3M

Acerca de Mainz BioMed NV

Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results. Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.

Sector
Testing Laboratories
Industria
Testing Laboratories
Sede
Amsterdam, North Holland, Nld
Fundado
-
Mainz BioMed NV is listed in the Testing Laboratories sector of the NASDAQ with ticker MYNZ. The last closing price for Mainz BioMed NV was US$0.25. Over the last year, Mainz BioMed NV shares have traded in a share price range of US$ 0.1852 to US$ 1.79.

Mainz BioMed NV currently has 21,165,482 shares in issue. The market capitalisation of Mainz BioMed NV is US$5.29 million.

MYNZ Últimas noticias

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in...

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with...

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

BERKELEY, Calif. and MAINZ, Germany, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in...

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.0052.040816326530.2450.35970.2123129687380.26828768CS
4-0.07-21.8750.320.35970.211349348590.26644964CS
12-0.1258-33.4752527940.37580.460.185232058220.28525036CS
26-0.45-64.28571428570.71.010.185219950640.3243144CS
52-0.99-79.83870967741.241.790.185210920470.38287709CS
156-10.73-97.72313296910.98300.18524423532.50978398CS
260-14.1-98.257839721314.35300.18524488962.68191349CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MTEMMolecular Templates Inc
US$ 0.60
(86.28%)
331.49M
QUBTQuantum Computing Inc
US$ 4.43
(66.54%)
232.55M
OMEROmeros Corporation
US$ 6.96
(66.11%)
14.23M
ADGMAdagio Medical Holdings Inc
US$ 3.71
(57.87%)
2.66M
VVPRVivoPower International PLC
US$ 1.18
(50.47%)
5.92M
SOWGSow Good Inc
US$ 4.23
(-56.88%)
2.91M
WCTWellchange Holdings Company Limited
US$ 4.08
(-48.35%)
1.27M
NVCTNuvectis Pharma Inc
US$ 5.73
(-46.30%)
1.71M
KXINKaixin Holdings
US$ 2.525
(-39.59%)
4.5M
TRNRInteractive Strength Inc
US$ 3.59
(-38.42%)
1.25M
ELABElevai Labs Inc
US$ 0.024658
(-0.17%)
1.79B
XTIAXTI Aerospace Inc
US$ 0.0565
(-1.22%)
363.98M
MTEMMolecular Templates Inc
US$ 0.60
(86.28%)
331.48M
SVMHSRIVARU Holding Ltd
US$ 0.0268
(10.74%)
245.93M
QUBTQuantum Computing Inc
US$ 4.43
(66.54%)
228.27M

MYNZ Discussion

Ver más
georgie18 georgie18 2 días hace
Thanks ...🥳...sold on a wash trade...https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175374580
👍️0
tw0122 tw0122 2 días hace
Absorbing 30 million shares from offering dropped Oct 30th at .26 cents 
👍️0
georgie18 georgie18 2 días hace
MYNZ...28...🥳...Psar flipped Bullish... https://schrts.co/DadDYwQx ..."W" in play here...

BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), through its subsidiary Life Technologies Corporation (“Thermo Fisher”), a world leader in supplying life sciences solutions and services.

The collaboration agreement will enable Mainz Biomed and Thermo Fisher to jointly develop and potentially commercialize Mainz Biomed’s Next Generation colorectal cancer screening product. The collaboration will harness Thermo Fisher’s powerful technologies, instrumentation and information translation systems to enable Mainz Biomed to develop the proprietary assays for its mRNA-based next-generation CRC screening tests which are redefining standards in early cancer detection. Mainz Biomed’s flagship non-invasive test not only targets the early detection of colorectal cancer but also focuses on precancerous lesions, particularly advanced adenomas, demonstrating significant clinical success in both US and European trials.

The collaboration will leverage combined capabilities to deliver testing solutions being developed at Mainz Biomed’s laboratories in Mainz, Germany.

Guido Baechler, CEO of Mainz Biomed, said: “This collaboration with Thermo Fisher will be instrumental to our goal to bring to market a home collection colorectal screening tool with highly effective detection of adenomas. Our product development will be greatly enhanced by Thermo Fisher’s knowledge and scalable, class-leading technologies, providing both partners with a means to accelerate the availability of an innovative new test for colorectal cancer screening around the world.”

Peter Jacobs, Director, EMEA Clinical Business Development, Thermo Fisher Scientific, said: “We are excited at the prospect of working with Mainz Biomed on their next generation screening test and are confident that together we will be able to achieve rapid progress and deliver innovative new assays for the global clinical marketplace.”
👍️0
glenn1919 glenn1919 2 días hace
MYNZ........................https://stockcharts.com/h-sc/ui?s=MYNZ&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 1 mes hace

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today increasing demand from existing and prospective laboratory partners for its enhanced ColoAlert product that has been launched in July 2024 and is currently being commercialized across Europe and in select international markets. This advanced version of the Company’s colorectal cancer (CRC) screening test is set to become the standard offering for all existing partners, reflecting its proven benefits in optimizing screening efficiency and improving user experience.
Widespread Transition to Enhanced ColoAlert

One of the earliest partners to make the transition is GANZIMMUN Diagnostics, one of Germany’s premier laboratories, which licensed the ColoAlert test. GANZIMMUN will fully implement the enhanced version of the innovative DNA biomarker-based screening product by the beginning of next year, taking advantage of the significant improvements in sample processing and usability that have set a new industry benchmark.

Improving Customer Interest

Partners are particularly drawn to the enhanced features, such as the proprietary DNA stabilizing buffer that ensures reliable results despite varying sample volumes, and the streamlined collection devices that simplify at-home testing for users. These innovations have drastically reduced the need for retesting, offering faster turnaround times for patients, with results available in just 2–3 days from sample arrival.

Promotion at Key Medical Event

GANZIMMUN Diagnostics will showcase the enhanced ColoAlert at the 57th Medizinische Woche Baden-Baden, a medical congress in Germany focusing on complementary medicine, which takes place from October 30 to November 3, 2024. This underscores the increasing role of complementary medicine in cancer prevention and early detection. The event will provide an ideal platform to promote Mainz Biomed’s innovative DNA-based CRC screening test to medical professionals, integrative medicine practitioners, and researchers interested in advanced diagnostic solutions.
"We are excited to support GANZIMMUN in introducing the enhanced ColoAlert at such a prestigious event," stated Tarrin Khairi-Taraki, VP Commercial Operations at Mainz Biomed. "The 57th Medizinische Woche Baden-Baden provides an excellent opportunity to demonstrate the importance of early colorectal cancer detection and how our innovations are making this process more efficient."

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
👍️0
georgie18 georgie18 1 mes hace
MYNZ...3964...🥳

georgie18

Member Level
Re: georgie18 post# 655458

Friday, September 27, 2024 10:28:12 AM

Post#
659577
of 660763
MYNZ...245...Reversal Candle setting up here...🥳

georgie18

Member Level
Re: georgie18 post# 175

Wednesday, August 28, 2024 8:08:19 AM

Post#
181
of 199
MYNZ...39s clearing here...Off my .44 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 655296

Monday, August 26, 2024 4:42:19 PM

Post#
655298
of 655457
MYNZ...44...on the 50MA Break...🥳
👍️0
mining101 mining101 2 meses hace
Spam and scam on social media - everywhere - bots and pumpers. Who is organizing that? No big volume still
👍️0
georgie18 georgie18 2 meses hace
MYNZ...245...Reversal Candle setting up here...🥳

georgie18

Member Level
Re: georgie18 post# 175

Wednesday, August 28, 2024 8:08:19 AM

Post#
181
of 199
MYNZ...39s clearing here...Off my .44 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 655296

Monday, August 26, 2024 4:42:19 PM

Post#
655298
of 655457
MYNZ...44...on the 50MA Break...🥳
👍️0
mining101 mining101 2 meses hace
Last uptick?
👍️0
Monksdream Monksdream 2 meses hace
MYNZ new 52 week low
👍️0
skydog526 skydog526 2 meses hace
Looks bad. No touch
👍️0
tiger_trader tiger_trader 2 meses hace
Any news on this? FDA decision?
👍️0
gatorhistory gatorhistory 2 meses hace
Waiting for news. Financials and fda response anyday imo
👍️0
tiger_trader tiger_trader 2 meses hace
Is this stock losing traction? Where is the FDA approval?
👍️0
Dcab Dcab 2 meses hace
Appears they got the FDA approval because the bleeding of the last few days has reversed. JMO
👍️0
Dcab Dcab 2 meses hace
Obviously there will be a buyout with the FDA approval and a big run up. They always drive the pps down right before the run up to buy as cheap possible. Always some sort of manipulation going on. JMHO.
👍️0
Dcab Dcab 2 meses hace
Obviously there will be a buyout with the FDA approval and a big run up. They always drive the pps down right before the run up to buy as cheap possible. Always some sort of manipulation going on. JMHO.
👍️0
81vette 81vette 2 meses hace
Dunno,shorts tearing into it today like a monkey eating a cupcake,shares to short went way up
👍️0
tiger_trader tiger_trader 2 meses hace
Will the FDA approve?
👍️0
ollik78 ollik78 2 meses hace
Will be interesting AH
Approval or Not
👍️ 1
mining101 mining101 2 meses hace
Ready
👍️0
81vette 81vette 2 meses hace
Charting up,FDA news expected,
👍️0
gatorhistory gatorhistory 2 meses hace
Bring on the fda news!
👍️0
mining101 mining101 2 meses hace
Little Fomo
👍️0
tiger_trader tiger_trader 2 meses hace
Will the FDA approve…?
👍️0
mining101 mining101 3 meses hace
Chart lines soon crossing
👍️0
georgie18 georgie18 3 meses hace
MYNZ...39s clearing here...Off my .44 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 655296

Monday, August 26, 2024 4:42:19 PM

Post#
655298
of 655457
MYNZ...44...on the 50MA Break...🥳
👍️0
FROZENFLAME FROZENFLAME 3 meses hace
Loading zone, IMO .
👍️0
tiger_trader tiger_trader 3 meses hace
Waiting on FDA decision
👍️0
FROZENFLAME FROZENFLAME 3 meses hace
Not in a hurry !
👍️0
gatorhistory gatorhistory 3 meses hace
Apparently no. Lol
👍️0
FROZENFLAME FROZENFLAME 3 meses hace
Can we see so 50s today !
👍️0
georgie18 georgie18 3 meses hace
MYNZ...44...on the 50MA Break...🥳
👍️0
FROZENFLAME FROZENFLAME 3 meses hace
45s looks like breakout on the way !
👍️0
FROZENFLAME FROZENFLAME 3 meses hace
You welcome, still waiting on volume, I think after hours should be interesting, GL .
👍️0
tiger_trader tiger_trader 3 meses hace
Ok thanks
👍️0
FROZENFLAME FROZENFLAME 3 meses hace
https://x.com/henryv64655/status/1828098998106026378?s=46&t=SOfgYFcNY1OxgkraPxHd4g
👍️ 1
mining101 mining101 3 meses hace
Nice outlook
👍️0
tiger_trader tiger_trader 3 meses hace
have you heard any projections on share price if the FDA approves?
👍️0
FROZENFLAME FROZENFLAME 3 meses hace
42s up
👍️0
FROZENFLAME FROZENFLAME 3 meses hace
Volume in !
👍️0
FROZENFLAME FROZENFLAME 3 meses hace
Creeping up !
👍️0
FROZENFLAME FROZENFLAME 3 meses hace
I’m not sure if that’s good or bad, maybe people loading, waiting on news, the last PR was about a month ago, and it’s moving on Friday, that’s what got my attention, hopefully we will get some news next week, it’s about time, IMO .
👍️0
tiger_trader tiger_trader 3 meses hace
Quiet board
👍️0
FROZENFLAME FROZENFLAME 3 meses hace
Coming off the 52WL, let’s see if we can get some attention, in for now !
👍️0
tiger_trader tiger_trader 3 meses hace
Invest at your own risk!!!


https://stocktwits.com/BreakoutMaster8/message/583420341
👍️0
Monksdream Monksdream 3 meses hace
MYNZ new 52 week low
👍️0
tiger_trader tiger_trader 3 meses hace
$MYNZ is about to explode! Just saw an alert: #FDA submission is done, and they’re targeting massive partnerships! 🚀📷 #DiamondHands #BuyTheDip #HBDSurBeryliyaciaga #BalenciagaxMilk $AAPL $GME #8YearsWithBLACKPINK #internationalcatday $AMC $AMZN #Biden #ToTheMoon #YOLO pic.twitter.com/VpWDEA9utO— Julia Thompson (@ouma15) August 8, 2024
👍️0
tiger_trader tiger_trader 3 meses hace
https://www.rttnews.com/3458713/mainz-biomed-seeks-fda-breakthrough-status-for-next-generation-crc-screening-test.aspx
👍️0
tiger_trader tiger_trader 3 meses hace
This board is very quiet
👍️0

Su Consulta Reciente

Delayed Upgrade Clock